<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
04.04.2020 14:47:00

Should You Buy Forty Seven Before Gilead Sciences' Acquisition Closes?

On March 3, Gilead (NASDAQ: GILD) announced it had reached an agreement to buy Forty Seven (NASDAQ: FTSV) for approximately $4.9 billion in cash. The deal, approved by the boards of both companies, is expected to close in the second quarter. The question remains whether it makes sense for biotech investors to own shares of Forty Seven before the acquisition is completed.Forty Seven, an up-and-coming immuno-oncology drug developer, provides a clinical-stage cancer drug and a pipeline of other earlier-stage therapies for Gilead. This adds to Gilead's relatively recent expansion into immuno-oncology, which began with its 2017 buyout of Kite Pharma for $11.9 billion. Kite is focused on cell therapy approaches that use the body's own immune system to fight cancers. Image Source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

(Anzeige)Passende emittierte Barrier Reverse Convertibles

Basiswert Valor Fälligkeitstag Maximale Rendite p.a.
Gilead Sciences Inc. / Johnson & Johnson / Pfizer Inc. 39255387 05.08.2020 5.80 %

Analysen zu Gilead Sciences Inc.mehr Analysen

15.03.19 Gilead Sciences Outperform BMO Capital Markets
03.01.19 Gilead Sciences Outperform Oppenheimer & Co. Inc.
26.10.18 Gilead Sciences overweight Barclays Capital
01.10.18 Gilead Sciences Overweight Cantor Fitzgerald
26.07.18 Gilead Sciences Neutral Robert W. Baird & Co. Incorporated

Eintrag hinzufügen

Aktien Top Flop

CS Group 9.18
3.22 %
Alcon 60.24
2.80 %
The Swatch Grp 196.25
2.59 %
Roche Hldg G 339.05
2.09 %
LafargeHolcim 40.10
2.09 %
SGS 2’227.00
0.86 %
Geberit 466.70
0.76 %
Novartis 81.74
0.69 %
Swiss Life Hldg 350.20
0.66 %
UBS Group 10.47
0.43 %
Ruhige Woche bahnt sich an | BX Swiss TV

Aktien in diesem Artikel

Gilead Sciences Inc. 66.00 3.77% Gilead Sciences Inc.

Finanzen.net News